[1]方潇,戴天增,池哲子,等.良性前列腺增生和男性群体膀胱癌的因果效应:双样本孟德尔随机化研究[J].福建医药杂志,2024,46(06):1-5.[doi:10.20148/j.fmj.2024.06.001]
　FANG Xiao,DAI Tianzeng,CHI Zhezi,et al.Causal effects of benign prostatic hyperplasia and bladder cancer in male population: a two-sample Mendelian randomization study[J].FUJIAN MEDICAL JOURNAL,2024,46(06):1-5.[doi:10.20148/j.fmj.2024.06.001]
点击复制

良性前列腺增生和男性群体膀胱癌的因果效应:双样本孟德尔随机化研究()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年06期
页码:
1-5
栏目:
专论
出版日期:
2024-11-15

文章信息/Info

Title:
Causal effects of benign prostatic hyperplasia and bladder cancer in male population: a two-sample Mendelian randomization study
文章编号:
1002-2600(2024)06-0001-05
作者:
方潇1; 戴天增1; 池哲子2; 朱兰卉2; 高帅1; 葛茹茹1; 周智华1
1 福建医科大学孟超肝胆医院泌尿外科,福州 350001; 2 福州大学生命科学与工程学院,福州 350116
Author(s):
FANG Xiao1;  DAI Tianzeng1;  CHI Zhezi2;  ZHU Lanhui2;  GAO Shuai1;  GE Ruru1;  ZHOU Zhihua1
1 Department of Urology, MengChao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350001, China; 2 College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350116, China
关键词:
膀胱癌;  良性前列腺增生;  单核苷酸多态性;  孟德尔随机化
Keywords:
bladder cancer;  benign prostatic hyperplasia;  single nucleotide polymorphism;  Mendelian randomization
分类号:
R737.14
DOI:
10.20148/j.fmj.2024.06.001
文献标志码:
A
摘要:
目的 利用两样本孟德尔随机化(MR)法探究良性前列腺增生(BPH)与男性群体膀胱癌(BCa)患病风险的因果效应。方法 分别获取来自FinnGen R9数据库的BPH暴露数据(n=172 961)以及UK Biobank的BCa结果数据(n=167 020)的全基因组关联研究数据,经筛选使用其中显著的单核苷酸多态性位点作为工具变量,利用MR-PRESSO检验、MR Egger法和逆方差加权(IVW)法行异质性检验,去除离群值。使用MR Egger法、加权中值估计法、IVW法行MR分析,判断两者的因果联系。使用MR Egger回归检验、留一法检测结果的敏感性与多效性,确保分析结果可靠。结果 在MR分析中,MR Egger法[OR=0.999 9, 95%CI=(0.995 5,1.003 6), P=0.832]、加权中值估计法[OR=0.999 9, 95%CI=(0.998 3,1.001 5), P=0.941]、IVW法[OR=1.000 1, 95%CI=(0.999 0,1.001 2), P=0.898]均未发现男性人群中BPH与BCa的风险之间存在因果关系。未发现显著的异质性或多效性,敏感性分析也没有发现与该假设相悖的结果。结论 孟德尔随机化研究不支持良性前列腺增生与男性群体膀胱癌患病存在因果效应。
Abstract:
Objective To explore the causal effect of benign prostatic hyperplasia(BPH)on the risk of bladder cancer(BCa)in the male population using the two-sample Mendelian randomization(MR). Methods Genome-wide association study data for BPH exposure data(n=172 961)from the FinnGen R9 database and BCa outcome data(n=167 020)from the UK Biobank were obtained. Significant single nucleotide polymorphism loci were selected as instrumental variables after screening. Heterogeneity tests were conducted using the MR-PRESSO test, MR Egger method, and the inverse variance-weighted(IVW)method to remove outliers. MR analyses were performed using the MR Egger method, weighted median estimate, and IVW method to assess the causal relationship. The sensitivity and pleiotropy of the results were tested using MR Egger regression test and leave-one-out method to ensure reliability of the analysis. Results In this MR analysis, no causal relationship was found between BPH and the risk of BCa in the male population using the MR Egger method, weighted median estimate, and IVW me-thod. No significant heterogeneity or pleiotropy was detected, and sensitivity analysis did not reveal any results contrary to the hypothesis.Conclusion Mendelian randomization study does not support a causal effect of benign prostatic hyperplasia on the incidence of bladder cancer in the male population.

参考文献/References:

[1] BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer(Ta, T1, and carcinoma in situ)[J]. European Urology, 2022, 81(1): 75-94.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA: A Cancer Journal for Clinicians, 2021, 71(1): 7-33.
[3] RICHTERS A, ABEN K K H, KIEMENEY L A L M. The global burden of urinary bladder cancer: an update[J]. World Journal of Urology, 2019, 38(8): 1895-1904.
[4] LEE Y J, LEE J W, PARK J, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea[J]. Investigative and Clinical Urology, 2016, 57(6): 424-430.
[5] DAI X, FANG X M, MA Y, et al. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies[J]. Medicine, 2016, 95(18): e3493.
[6] HUNG S C, LAI S W, TSAI P Y, et al. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk[J]. Br J Cancer, 2013, 108(9): 1778-1783.
[7] FANG C W, LIAO C H, WU S C, et al. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study[J]. World J Urol, 2018, 36(6): 931-938.
[8] DU W, WANG T, ZHANG W, et al. Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: a mendelian randomization study[J]. Frontiers in Genetics, 2022, 13: e1016696
[9] GREENWALD P, KIRMSS V, POLAN A K, et al. Cancer of the prostate among men with benign prostatic hyperplasia[J]. Journal of the National Cancer Institute, 1974, 53(2): 335-340.
[10] KANG D, CHOKKALINGAM A P, GRIDLEY G, et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer[J]. British Journal of Cancer, 2007, 96(9): 1475-1479.
[11] FU Y, LI J, ZHU Y, et al. Causal effects of gut microbiome on autoimmune liver disease: a two-sample Mendelian randomiza-tion study[J]. BMC Med Genomics, 2023, 16(1): 232.
[12] KURKI MI, KARJALAINEN J, PALTA P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population[J]. Nature, 2023, 613(7944): 508-518.
[13] SUDLOW C, GALLACHER J, ALLEN N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age[J]. PLoS Medicine, 2015, 12(3): e1001779.
[14] BURGESS S, THOMPSON S G. Avoiding bias from weak instruments in Mendelian randomization studies[J]. International Journal of Epidemiology, 2011, 40(3): 755-764.
[15] SEKULA P, DEL GRECO M, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. Journal of the American Society of Nephrology, 2016, 27(11): 3253-3265.
[16] YUH B, WILSON T, BOCHNER B, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy[J]. European Urology, 2015, 67(3): 402-422.
[17] LIN Y H, HOU C, JUANG H, et al. Association between bladder outlet obstruction and bladder cancer in patients with aging male[J]. J Clin Med, 2019, 8(10): 1550.
[18] GRATZKE C, BACHMANN A, DESCAZEAUD A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction[J]. European Urology, 2015, 67(6): 1099-1109.

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金面上项目(2020J011172)
通信作者:周智华,Email: 6485801@qq.com
更新日期/Last Update: 2024-11-15